Covered recipient · General Payments record
PAUL A MALABANAN
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2020–2024
$1,464.51
- Reported across 62 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $362.71 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $146.66 | 8 |
| Janssen Pharmaceuticals, Inc | $138.05 | 5 |
| Merck Sharp & Dohme Corporation | $28.71 | 1 |
| ABBVIE INC. | $18.25 | 1 |
| Novo Nordisk AS | $16.56 | 1 |
| Amgen Inc. | $14.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.25 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104938109 | CMS |
| Amgen Inc. | $14.48 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117617998 | CMS |
| Janssen Pharmaceuticals, Inc | $22.49 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077932645 | CMS |
| Janssen Pharmaceuticals, Inc | $27.83 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077932647 | CMS |
| Janssen Pharmaceuticals, Inc | $28.14 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077932649 | CMS |
| Janssen Pharmaceuticals, Inc | $29.25 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077932639 | CMS |
| Janssen Pharmaceuticals, Inc | $30.34 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077932637 | CMS |
| Lilly USA, LLC | $28.55 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135281394 | CMS |
| Lilly USA, LLC | $5.70 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135272615 | CMS |
| Lilly USA, LLC | $4.02 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135280979 | CMS |
| Lilly USA, LLC | $4.69 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135310502 | CMS |
| Lilly USA, LLC | $31.47 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135310505 | CMS |
| Lilly USA, LLC | $17.87 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135272619 | CMS |
| Lilly USA, LLC | $31.53 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135318338 | CMS |
| Lilly USA, LLC | $22.83 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135280975 | CMS |
| Merck Sharp & Dohme LLC | $28.71 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141573541 | CMS |
| Novo Nordisk Inc | $16.56 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097523822 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.